| Original language | English |
|---|---|
| Pages (from-to) | 21-27 |
| Number of pages | 7 |
| Journal | Clinical and Translational Science |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2018 Jan |
ASJC Scopus subject areas
- Neuroscience(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology, Toxicology and Pharmaceutics(all)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Clinical and Translational Science, Vol. 11, No. 1, 01.2018, p. 21-27.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Future of Rare Diseases Research 2017–2027
T2 - An IRDiRC Perspective
AU - on behalf of the International Rare Diseases Research Consortium (IRDiRC)
AU - Austin, Christopher P.
AU - Cutillo, Christine M.
AU - Lau, Lilian P.L.
AU - Jonker, Anneliene H.
AU - Rath, Ana
AU - Julkowska, Daria
AU - Thomson, David
AU - Terry, Sharon F.
AU - de Montleau, Béatrice
AU - Ardigò, Diego
AU - Hivert, Virginie
AU - Boycott, Kym M.
AU - Baynam, Gareth
AU - Kaufmann, Petra
AU - Taruscio, Domenica
AU - Lochmüller, Hanns
AU - Suematsu, Makoto
AU - Incerti, Carlo
AU - Draghia-Akli, Ruxandra
AU - Norstedt, Irene
AU - Wang, Lu
AU - Dawkins, Hugh J.S.
N1 - Funding Information: Acknowledgments. The authors thank the present representatives of the IRDiRC Consortium Assembly, present members of the IRDiRC Scientific Committees, and Scientific Secretariat for their contribution to this collaborative effort (see Supplementary Information). The authors would also like to thank all participants of the 3rd IRDiRC Conference in Paris for their feedback on the vision and goals for the next decade. IRDiRC Scientific Secretariat is supported by the European Commission FP7 contract, “SUPPORT-IRDiRC” (No 305207) and HL is supported by the European Commission FP7 contract, “RD-Connect” (No 305444). CPA has contributed to this work in his capacity as Chair of the IRDiRC Consortium Assembly, not in his role as director of the National Center for Advancing Translational Sciences. Funding Information: The authors thank the present representatives of the IRDiRC Consortium Assembly, present members of the IRDiRC Scientific Committees, and Scientific Secretariat for their contribution to this collaborative effort (see Supplementary Information). The authors would also like to thank all participants of the 3rd IRDiRC Conference in Paris for their feedback on the vision and goals for the next decade. IRDiRC Scientific Secretariat is supported by the European Commission FP7 contract, ?SUPPORT-IRDiRC? (No 305207) and HL is supported by the European Commission FP7 contract, ?RD-Connect? (No 305444). CPA has contributed to this work in his capacity as Chair of the IRDiRC Consortium Assembly, not in his role as director of the National Center for Advancing Translational Sciences. The views expressed in this publication are the sole responsibility of the authors and do not necessarily reflect the views of their affiliated organizations. Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use which might be made of the information. CPA contributed in his capacity as Chair of the IRDiRC Consortium Assembly, not in his role as the Director of the National Center for Advancing Translational Sciences.
PY - 2018/1
Y1 - 2018/1
UR - http://www.scopus.com/inward/record.url?scp=85040288351&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040288351&partnerID=8YFLogxK
U2 - 10.1111/cts.12500
DO - 10.1111/cts.12500
M3 - Review article
C2 - 28796445
AN - SCOPUS:85040288351
SN - 1752-8054
VL - 11
SP - 21
EP - 27
JO - Clinical and Translational Science
JF - Clinical and Translational Science
IS - 1
ER -